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Mdm2The Ubiquitin Proteasome Pathway (UPP) has become a target rich pathway for therapeutic intervention as
its role in pathogenic disease is better understood. In particular many E3 ligases within this pathway have
been implicated in cancer, inﬂammation and metabolic diseases. It has been of great interest to develop
biochemical assays to identify inhibitors of catalytic E3 ubiquitination activity as a means of abrogating the
disease mechanism. Here we describe a homogeneous biochemical assay that utilizes native ubiquitin and
Tandem-repeated Ubiquitin-Binding Entities (TUBEs) as a detection technology for ubiquitination activity.
We developed a TUBEs based proximity AlphaLisa® assay for Mdm2, which is an E3 ligase that negatively
regulates p53 tumor suppressor protein. We further demonstrate that this assay strategy or design can also
be applied to the development of assays to detect autoubiquitination of other E3 ligases that are also of
interest for therapeutic intervention. This article is part of a Special Issue entitled: Ubiquitin Drug Discovery
and Diagnostics.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The covalent postranslational modiﬁcation of protein substrates
with ubiquitin is of growing interest to the pharmaceutical industry
as the process regulates proteins involved in many cellular functions,
to include cell cycle, cell motility, transcriptional regulation, receptoray; E1, ubiquitin activating
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l rights reserved.internalization and protein trafﬁcking [1–3]. The process of ubiquitin
ligation consists of a three enzyme cascade that begins with the
activation of ubiquitin by a ubiquitin activating enzyme, E1, which
forms a high energy thioester bond with ubiquitin. The activated
ubiquitin is then passed to a ubiquitin conjugating enzyme, E2, and
then the E2-ubiquitin conjugate is brought together with an E3
ubiquitin ligase and it is the E3 in complex with the E2 and substrate
that facilitates the transfer of ubiquitin to the substrate protein
(Fig. 1). The protein components within the pathway can potentially
be modulated by small molecules, and given the fact that there are
>600 ubiquitin ligases that exist [4], this process is being examined
for therapeutic intervention. Many ubiquitin ligases possess an
intrinsic autoubiquitination activity which we have used as a read
out for the catalytic activity of the ligase complex.
Indeed this approach has been utilized to screen for, and identify,
small molecule inhibitors of Mdm2 ubiquitination activity [5]. Two
biologically alluring ubiquitin ligases that might provide therapeutic
value are Mdm2 and Traf6. Mdm2 is the ligase dedicated to regulating
the tumor suppressor p53 [6,7], and as such, inhibition of Mdm2
catalytic activity would provide increased amounts of p53 to the cell.
In support of this, evidence exists that transformed cells are more
sensitive to p53 induced apoptosis and therefore increases in p53
may sensitize tumor cells to increased cell death [8,9]. Traf6 is an E3
ligase that plays a role in canonical NFκB activation. Upon TNFR, IL-1R
and TLR stimulation, Traf6 is activated, leading to a cascade which
Fig. 1. Ubiquitination pathway. The ubiquitination pathway is a cascading reaction
involving several proteins. The ﬁrst step in the reaction is enzyme E1 activation in the
presence of ATP and ubiquitin by forming a high energy thioester bond between
ubiquitin and E1. The E2 is then charged by the transfer of ubiquitin from an activated
E1 to the E2, also by a thioester bond. Finally, a substrate is ubiquitinated when
complexed with the charged E2 and a substrate speciﬁc E3 that facilitates the transfer
of ubiquitin from E2 to substrate. In the absence of a substrate many E3s are known to
be themselves the substrate via an autoubiquitination reaction.
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Inhibition of this cascade with small molecules, and speciﬁcally the
activity of Traf6, would result in the inhibition of NFκB activation and
the inﬂammatory responses it regulates.
A number of assay technologies have been developed to identify
small molecule inhibitors of ubiquitin ligases. These technologies
include plate based assays such as electrochemiluminescence (ECL)
[11,12] and homogeneous assays such as Time Resolved Fluorescence
Resonance Energy Transfer (TR-FRET) [13]. Here we describe the
development of a homogeneous autoubiquitination assay utilizing
the PerkinElmer AlphaLISA® technology and ubiquitin binding
matrices (TUBEs) [14], as a universal component for the detection of
ubiquitinated proteins. This approach provides the sensitivity of the
AlphaLISA® technology, relative simplicity as a homogeneous assay
and is advantageous since native ubiquitin is used, eliminating the
need to optimize assay conditions and ratios of tagged ubiquitin
molecules to native ubiquitin, which other homogeneous assay
formats require. Additionally, the utilization of native ubiquitin
eliminates the possibility of a tagged ubiquitin interfering in the
kinetics of the ubiquitination event.
2. Materials and methods
2.1. Puriﬁcation of recombinant proteins
Human Ube1 gene encoding amino acids 2–1058 (Genbank
accession CAA40296) was PCR ampliﬁed from a liver cDNA library
(Amgen) and cloned into pFastBac1 H6T vector through an enzyme-
free cloning method as described previously [15]. UBE1 (2–1058)
was then expressed in sf9 insect cells as an N-terminal His6 fusion
protein using Bac-to-Bac Baculovirus Expression Systems (Invitrogen,
Carlsbad, CA). The preparation of BacMid and production of recom-
binant baculovirus were carried out according to the manual of
Bac-to-Bac system (Invitrogen). The full length Ube1 protein was
expressed by infecting mid-log phasesf9cells (2.5×106 cells/ml)
with a high-titer baculovirus stock at a MOI of 5–10. Insect cells
were then cultured in sfx medium (Hyclone) at 27°C for 48 h.
Recombinant His-tagged UBE1 expressed from Sf9 insect cells issequentially puriﬁed through three steps: cell lysis, Nickel (Sigma)
afﬁnity chromatography and gel ﬁltration (Superdex 200, Amersham
Biosciences). The cell paste was resuspended in lysis buffer, 50 mM Tris,
pH 8.0, 150 mM NaCl, 5 mM β-mercaptoethanol, supplemented with
complete protease inhibitor mixture (Sigma), and disrupted by micro-
ﬂuidizer. Cell debris was removed by centrifugation (45,000 g, 1.5 h, 4),
and then, the supernatant was incubated for overnight at 4°C with
Nickel resin (Sigma). The resin was washed with 20 CV of lysis buffer
and lysis buffer containing 10 mM imidazole ﬁrst, then eluted target
protein with lysis buffer containing 100 mM imidazole. The eluted
protein solutionwas concentrated to a small volume, andwas loaded on
Gel-Filtration column (Superdex 200, XK16) which was equilibrated in
20 mM Tris, pH8, 150 mM NaCl, 1 mM β-mercaptoethanol. The ﬁnal
protein purity was about 95% based on SDS-PAGE. A clone of huSmurf1
was obtained fromOrigene (Rockville,MD). The genewas PCR ampliﬁed
using the following oligo pair:
5′-AAC AAC AAC GGT CTC GGA TCC ATG TCG AAC CCC GGG ACA
CGC AG-3′//5′-CCG CCG CCG GAA TTC CTA TTA CTC CAC AGC AAA CCC
GCA GGT CTC-3′. The product was puriﬁed with a QIAquick PCR
puriﬁcation kit (Qiagen), digested with BamHI and EcoRI and cloned
into pGEX2T (GE Healthcare). The insert was sequence conﬁrmed.
Expression was done at 16 °C in strain BL21-Codon Plus-RIL
(Stratagene) in TB media supplemented with 100 μg/ml carbenicillin
and 30 μg/ml chloramphenicol. The culture was induced with 0.2 mM
IPTG at about 1 OD and induction went overnight. Cell pellets were
resuspended in 25 mM Tris–HCl (pH 7.5), 0.15 M NaCl, 0.1% CHAPS,
5 mM DTT, 10% glycerol and Complete “Free” protease inhibitor
cocktail (Roche) and lysed by a microﬂuidizer. Lysate was cleared by
centrifugation at 14 K rpm for 2 h and ﬁltered through a 0.45 μm
cellulose acetate membrane before application to Glutathione
Sepharose 4B beads (GE Biosciences) for one hour batch-incubation
at 4 °C. The beads were washed extensively with same buffer and
protein was eluted with the buffer containing 10 mM reduced
glutathione. The elution was loaded on Superdex 200 XK 26/60
column (GE Biosciences) equilibrated with 25 mM Tris–HCl (pH 8.0),
0.15 M NaCl, 5% glycerol, 0.1% CHAPS and 5 mM DTT.
The protein identity was conﬁrmed by LC–MS and concentrations
were determined using Bradford assay, and snap frozen in liquid
nitrogen and stored at −80 °C.
A DNA fragment encoding TRAF6 (1–181) was ampliﬁed from the
full length TRAF6 DNA template using PCR primers: GACTACTAGTGA-
GAACCTCTACTTCCAGGGAAGTCTGCTAAACTGTGAAAACAGC (F) and
GCG AAT TCA ATC CTT CAG AAT GTG AAT ATT AAT ATG (R). The
bacterial expression plasmid pET42 GST-Tev-TRAF6 (1–181) was
constructed by inserting the SpeI and EcoRI (New England Biolabs)
double digested PCR fragment into the pre-digested pET42 vector
(Novagen). To express recombinant TRAF6 (1–181) protein, BL21
(DE3) cells carrying pET42 GST-Tev-TRAF6 (1–181) plasmid were
grown in TB at 37°C, and induced by 1 mM IPTG at 18°C overnight.
The protein was ﬁrst puriﬁed by GST afﬁnity chromatography and
sequentially by size-exclusion chromatography (Pharmacia S200) in a
buffer containing 20 mM Tris pH8, 5% glycerol, 100 mM NaCl, 5 mM
βME. Uev1A gene was ampliﬁed a cDNA library (Amgen) using PCR
primers: GAC TAC CGG TGA GAA CCT CTA CTT CCA GGG ACC AGG AGA
GGT TCA AGC GTC (F) and GAC TAC CGG TGA GAA CCT CTA CTT CCA
GGG ACC AGG AGA GGT TCA AGC GTC (R). The PCR product was then
digested by AgeI and BamHI (NEB) and cloned into pET45 (Novagen)
between AgeI and BamHI sites. The recombinant Uev1A proteinwith a
His6 tag followed by a Tev cleavage site at its N-terminus was
expressed in BL21 (DE3) cells under the same conditions as TRAF6
(1–181). The frozen cell paste was resuspended in lysis buffer (35 mM
Tris pH8, 5% glycerol, 150 mM NaCl, 5 mM BME, cocktail protease
inhibitors) and lysed by microﬂuidizer. The lysate was centrifuged,
ﬁltered and mixed with Nickel afﬁnity resin, then, slowly rocked at
4°C overnight. After low imidazole washing, target protein was eluted
with 150 mM imidazole buffer. The eluted target protein was
2040 S. Schneider et al. / Biochimica et Biophysica Acta 1823 (2012) 2038–2045concentrated, and loaded onto size exclusion column (Pharmacia
S200) with 20 mM Tris pH8, 5% glycerol, 100 mM NaCl, 5 mM BME
buffer. The ﬁnal target protein is about 95% pure based on SDS PAGE.
The humanUBE2D2 (Ubch5b), and SUMO-Hrd1, were purchased from
LifeSensors (Malvern, PA). His-Mdm2 and ubiquitin were purchased
from Boston Biochem, Inc. (Cambridge, MA).
2.2. Detection
Glutathione and Streptavidin AlphaScreen® donor beads, Protein
A AlphaLISA® acceptor beads and white 384 shallow well ProxiPlates
™-384 Plus shallow well microplates were purchased from PerkinEl-
mer (Waltham, MA). TUBEs1 and TUBEs2 were purchased from
LifeSensors (Malvern, PA). Mdm2 mouse monoclonal antibody
(smp14) was ordered from Abcam (Cambridge, MA), Hrd1 rabbit
polyclonal antibody (C-term) from Abgent, Inc. (San Diego, CA),
Smurf1 goat polyclonal antibody (F-20) from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA) and Traf6 rabbit polyclonal antibody from Cell
Signaling Technology Inc. (Danvers, MA).
2.3. In vitro ubiquitination and data acquisition/analysis
Mdm2 autoubiquitination assay: The AlphaLISA® Assay used
white 384 shallow well ProxiPlate-384TM PLUS microplates. The
reaction buffer is composed of 50 mM HEPES pH 7.5, 5 mM MgCl2,Fig. 2. Enzyme titrations. All graphs measure MDM2 autoubiquitination activity. A) E1 was ti
1000 nM in 2 fold dilution steps to 16.5 nM for each concentration of ubiquitin (titrated in t
D) Signal to background increases dose dependently with Mdm2 concentration. E) Rate o
range is outlined and inset).100 mM NaCl, 0.005% Tween-20 and 1 mM DTT. All assay conditions
were carried out at room temperature. The E2 is precharged in
reaction with 10 nM His-E1, 250 nM His-Ubch5b (E2), 250 nM
Ubiquitin and 1 mM ATP for 30 min. Simultaneously, 2 μl of 5 nM
His-Mdm2 (E3) is added to 2 μl of reaction buffer containing 2.8%
DMSO (compound mimic). His-Mdm2 autoubiquitination activity is
initiated when 2 μl of precharge is added to the His-Mdm2/DMSO
mix, yielding a 6 μl total reaction that is incubated for 60 min. The
assay was stopped with 5 μl stop/detection mix containing: 30 mM
EDTA, 15 mM DTT, 2.5 μg/ml protein A AlphaLISA® acceptor beads,
0.5 μg/ml anti-Mdm2 antibody, 2.5 μg/ml glutathione AlphaScreen®
donor beads and 2.5 μg/ml GST-TUBEs1 (the acceptor bead, anti-
Mdm2 antibody, glutathione donor bead and GST-TUBEs1 were pre-
incubated for 60 min prior to the addition of EDTA and DTT). Due to
the nature of AlphaLISA® technology the stop/detection addition was
performed under reduced light conditions so as not to photo-bleach
the detection reagents. The assay was covered with an opaque light
blocking seal and incubated overnight. The plates were read on an
Envision® multi label reader using the default program set with laser
excitation at 680 nM and emission at 615 nM. Data analysis was
performed using Microsoft Excel® and Graphpad Prism®. We carried
out the Mdm2 assay uniformity using the above described reaction
conditions. We used the Multidrop Combi from Thermo Scientiﬁc as
our reagent dispenser. 1 μl of stop buffer (30 mM EDTA, 15 mM DTT)
was added to 192 wells prior to the plating of the Mdm2trated from 80 nm in 2 fold dilution steps to 1.25 nM. B) Ubch5b (E2) was titrated from
he same range). C) Mdm2 (E3) was titrated from 20 nM in 2 fold dilutions to 0.031 nM.
f reaction Mdm2 autoubiquitination activity plotted against concentration (the linear
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backround or “LO” control signal. 1 μl of stop buffer was added
to the other 192 wells after an hour of reaction incubation to
provide an autoubiquitination activity signal within the linear
range of the assay as our “HI” control signal. The signal to back-
ground (S:B) was determined by dividing the averaged HI signal
by the averaged LO signal (S:B=S/B). The quality of the assay was
determined using Z′ calculation Z′=1−(((3*standard deviation
of HI signal)+(3*standard deviation of LO signal)) / (average HI
signal−average LO signal)).
3. Results
The goal of this effort was to develop an autoubiquitination assay
that could be utilized in a high throughput screening (HTS) campaign.
We chose to use the AlphaLISA® assay technology because it enables
a homogeneous assay that can often be performed in a small volume
which makes it amenable to an HTS setting. In addition, this assay
technology is able to detect interactions that span a larger distance
than those that can be measured by TR-FRET. The singlet oxygen that
is emitted from the AlphaLISA donor bead can excite an acceptor bead
that is up to 200 nm away; however, TR-FRET is generally limited to a
distance of 9 nm between the donor and acceptor ﬂuors. This distance
may be important in characterizing a growing polyubiquitin chain
which adds 8.5 kDa ubiquitin molecules in succession. Traditional
assay methods require the use of a labeled ubiquitin molecule for
detection, which has the potential to alter the kinetics of ubiquitin
conjugation. For this reason, our development included the use of the
TUBEs technology as our ubiquitin chain detector, which is composed
of tandem repeats of UBA ubiquitin binding domains, allowing us toFig. 3. Reaction components. All graphs represent Mdm2 autoubiquitination activity (enzym
are within the linear range of the assay. A) Tween-20 titration from 0.04% titrated down 2
0.125 mM. C) DMSO titration from 10% titrated down 2 fold to 0.156%. D) Glutathione Alpha
titrations GST-TUBEs1 was titrated 2 fold from 22 μg/ml to 0.3437 μg/ml. Protein A AlphaLIutilize unlabeled ubiquitin in our assay. (Additionally we are able to
characterize ubiquitin chain formation using unlabeled ubiquitin
derivatives.) We used the well characterized Mdm2 ubiquitin ligase
as the E3 component in our assay development.
Initially, we set out to demonstrate the dependency of each of the
proteins involved in the ubiquitin transfer cascade on the kinetics of
the reaction, as well as to optimize their concentrations to obtain a
linear 60 minute Mdm2 autoubiquitination reaction. Using reaction
conditions previously developed in our lab (E2 Ubch5b 250 nM,
ubiquitin 150 nM E3 Mdm2 2.5 nM), we titrated E1 enzyme to
determine the range for optimal activity. Activity was detected as low
as 1.25 nM with a peak of activity at 20 nM and then a decrease of
activity in excess of 40 nM. Our results indicate that in the absence of
E1 activating enzyme there is no autoubiquitination of Mdm2
demonstrating the dependence of E1 for the reaction (Fig. 2a). Next,
we ﬁxed the E1 concentration at 10 nM which was determined to be
within the linear range as well as providing an acceptable signal to
background, and titrated the E2 conjugating enzyme under increasing
concentrations of ubiquitin. Activity was observed at E2 concentra-
tions as low as 20 nM and plateaued at 500 nM. Autoubiquitination
activity was dependent on ubiquitin and the activity increased in a
dose dependent manner but plateaued when it reached the same
concentration of E2 used in each titrated reaction. This suggests a 1:1
relationship of E2 to ubiquitin for the optimal detection of
autoubiquitination (Fig. 2b). Similar to the E1, there is a requirement
of E2 and ubiquitin for the autoubiquitination of Mdm2 (Fig. 2c).
Finally we ﬁxed the E2 and ubiquitin concentrations at 250 nM and
titrated His-Mdm2 for the E3 linearity. Mdm2 showed linear
autoubiquitination activity for 60 min with concentrations ranging
from 30 pM to 5 nM of Mdm2. In further studies we chose 1.25 nMe concentrations: 10 nM E1, 250 nM E2 and 250 nM ubiquitin) at 60 min and all data
fold to 0.000625%. B) Dithiothreitol (DTT) titration from 8 mM titrated down 2 fold to
Screen® donor beads were titrated 2 fold from 20 μg/ml to 2.5 μg/ml. For each of these
SA® Acceptor bead and anti-Mdm2 antibody concentration was ﬁxed at 2.5 μg/ml.
Fig. 4. E3 autoubiquitination TUBEs assay. All steps are carried out at room
temperature. Step 1: E2 is precharged with ubiquitin in the presence of ATP for a 30
minute reaction. Step 2: 2 μl of precharged E2 is added to 2 μl of E3 and 2 μl reaction
buffer/DMSO (compound mimic) and incubated in an autoubiquitination reaction for
60 min. Step 3: The assay is stopped by the addition of 5 μl stop/detection mix
consisting of EDTA and DTT to stop the assay activity. Detection of autoubiquitination
occurs when the pre-bound glutathione donor bead and GST-TUBEs reagent bind to the
polyubiquitin chain of the E3 and the speciﬁc antibody (a-Mdm2) pre-bound to the
protein A AlphaLisa® acceptor bead binds to Mdm2. The proximity of the
AlphaScreen® donor bead with the AlphaLisa® acceptor bead under laser excitation
of 680 nm sets off a cascading chemical reaction from which a singlet oxygen molecule
excites the acceptor bead emitting light that can be detected at 615 nm.
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the linear range when rate of reaction was graphed with respect to
enzyme concentration (Fig. 2d).
We also explored the limitations and requirements of other
components in the assay. The microplates as well as the bead based
AlphaLISA® detection reagents can be susceptible to non-speciﬁc
interactions and in order to minimize any non speciﬁc binding we
examined the effects of detergent on the assay. We titrated Tween-20
from 0.04% to 0.000625% in 2 fold dilution steps. The signal to noise
improves dramatically as the concentration approaches the max
concentration of 0.04% (Fig. 3a). We chose 0.005% going forward
because this provided a good signal to noise value and is below the
CMC for Tween-20 (Fig. 3a). Next we evaluated the effect of DTT, on
the assay. Activity is diminished and lost altogether at high
concentrations of DTT (>1 mM DTT) (Fig. 3b). This result is expected
as ubiquitin is linked to the E1 during activation and the E2 by a high
energy thioester bond. The ultimate goal of developing an E3
autoubiquitination assay is to screen compound libraries for in-
hibitors so it is essential to test DMSO tolerance. Our results show that
signal is signiﬁcantly reduced at concentrations greater than 2.5%
DMSO ﬁnal concentration in the assay (Fig. 3c).
We chose the AlphaLISA® detection technology due to its
suitability for our HTS platform. It is highly adaptable for a low
volume, automated, homogeneous assay for detection of E3 auto-
ubiquitination. As with many proximity based assays available, the
modularity of the assay is very desirable. For this assay we chose
donor beads that would interact speciﬁcally with the TUBEs
technology we were evaluating. Initially we explored the optimal
relationship between the GST-tagged TUBEs 1 and the glutathione
donor beads. We found that the optimal μg/ml relationship of
glutathione donor beads to TUBEs was 1:1 (Fig. 3d). The optimal
signal was achieved at our lowest tested concentration 2.5 μg/ml for
each reagent. Once we determined the initial conditions, we adapted
the protocol for differentially tagged TUBEs reagents.
For the acceptor bead, there are several capture modalities to
choose from depending on the E3 and its modiﬁcations. The Mdm2
full length E3 ligase used in this assay is His-tagged. The E1 and the E2
are also His-tagged, ruling out the possibility of using a nickel chelate
AlphaLISA® acceptor bead. For the acceptor bead we evaluated
protein A AlphaLISA® acceptor bead pre-bound to an anti-Mdm2
antibody. The antibody approach for the acceptor gives us the
speciﬁcity for Mdm2 and, we hoped, a way to add universality by
allowing for the substitution of a different E3-antibody pair.
The assay was set up as an 11 μl assay using PerkinElmer low
volume ProxiPlates™-384 Plus microplate. Brieﬂy, 2 μl reaction buffer
containing DMSO (1% ﬁnal concentration to simulate our compound
transfer step) was added to the ProxiPlate™. Next, 2 μl of Mdm2 in
reaction buffer was added to the DMSO-reaction mix. Finally, the
autoubiquitination reaction was initiated by adding 2 μl of pre-
charged E2 reaction buffer (E1-E2-Ub that was pre-incubated for
30 min). The Stop-Detection buffer was prepared by pre-incubating
GST-TUBEs, glutathione donor beads, anti-Mdm2 antibody and
protein A AlphaLISA® acceptor beads for 1 h. Then 30 mM EDTA pH
8.0 and 15 mM DTT (ﬁnal concentrations) were added as the stop
reagent to the detection mix and 5 μl of that solution was added to
the completed autoubiquitination assay (Fig. 4).
3.1. Universality of the ubiquitin binding matrices
Our goal was to develop an assay format that could be universal
in our approach to ligase drug discovery, and ultimately, we wanted
to determine if the Mdm2 autoubiquitination assay could be applied
to other E3 ligases using the TUBEs technology as a universal detector of
ubiquitination. Full length Sumo-Hrd1 (RING), GST-Smurf1 (HECT) and
a truncated GST-Traf61–181 (RING), that contains the N-terminus, the
RING ﬁnger, and the ﬁrst two Zinc Finger domains, were also tested forautoubiquitination activity (Fig. 5). The assay conditions were identical
for each of these ligases except for the following: the E2 for Traf6 which
requires Ubc13/Uev1a, the E2 (Ubch7) for Smurf1, and the speciﬁc E3
antibody used in the detection and the tagged version of TUBEs1. In
order not to interfere with the GST tag of Smurf1 and Traf6, we used
biotin-TUBEs1 and streptavidin AlphaScreen® donor beads in the
detection. Our results show linear activity up to 80 min for several
dilutions of Sumo-Hrd1 and GST-Traf6, while we could only achieve up
to 20 min of linear activity for GST-Smurf1.
The three TUBEs products have unique ubiquitin binding proper-
ties and they are available in a variety of tagged formats. The tag of
the protein components in the assay dictate what tags are appropri-
ate for the TUBEs used in the detection. The TUBEs1 binding proﬁle is
based on UBA binding domains from Ubiquilin. The afﬁnity of TUBEs1
for K63 linked tetra-ubiquitin is ~10 fold higher than K48 linked.
TUBEs2 contains UBA1 domains from RAD23A and the afﬁnity of
TUBEs2 for K63 and K48 linked tetra-ubiquitin is equivalent. Finally,
TUBEs 3 is based on yeast UBAs from RAD23A. It has an increased
afﬁnity for polyubiquitin chains over mono ubiquitin [14].
It has been demonstrated by MS that Mdm2 produces heteroge-
neous isopeptide linkages in polyubiquitin chains (K6, K11, K48, and
Fig. 5. E3 universality. A) SUMO-Hrd1 (RING E3) was titrated in 2 fold dilutions from 20 nm to .031 nM and autoubiquitination activity (10 nM E1, 250 nM E2 Ubch5b and 250 nM
ubiquitin) was measured up to 80 min. B) GST-Smurf1 (HECT E3) was titrated in 2 fold dilutions from 5 nM to .031 nM and autoubiquitination activity (10 nM E1, 250 nM E2 Ubch7
and 250 nM ubiquitin) up to 120 min. C) GST-Traf6 (RING E3) was titrated in 2 fold dilutions from 20 nm to 0.031 nM and autoubiquitination activity (10 nM E1, 100 nM E2 Uev1A/
Ubc13 and 500 nM ubiquitin) was measured up to 80 min.
2043S. Schneider et al. / Biochimica et Biophysica Acta 1823 (2012) 2038–2045K63) [16]. We analyzed all three TUBEs modalities to determine which
is best suited for evaluating an in vitro autoubiquitination assay.
Perhaps because of the heterogeneous nature of chain formation for
Mdm2 we observed little difference in results between TUBEs1 andFig. 6. Ubiquitin chain formations. A) Comparison of linear Mdm2 autoubiquitination activit
(wt-Ub, K48 only-Ub, K63 only-Ub and methylated-Ub) on Mdm2 autoubiquitination activity
methylated-Ub) on Traf6 autoubiquitination activity. D) Summary of the activity and chainTUBEs2. We could not assess the use of TUBE 3 because it was only
available with a His tag and Mdm2, E1 and Ubch5b (E2) were also His
tagged in the assay. We further investigated whether we could detect
speciﬁc ubiquitin linkages by replacing wild type ubiquitin withy using 2.5 μg/ml TUBEs1 and TUBEs2. B) Evaluating the effects of ubiquitin derivatives
. C) Evaluating the effects of ubiquitin derivatives (wt-Ub, K48 only-Ub, K63 only-Ub and
formation requirements between Mdm2 and Traf6 with respect to ubiquitin derivates.
Fig. 7. Mdm2 uniformity. We carried out the Mdm2 assay uniformity using the
described assay reaction conditions. Stop buffer was added to 192 wells prior to
reaction incubation to provide a background signal (LO). Stop buffer was added to the
other 192 wells after 60 min of reaction incubation to provide an autoubiquitination
activity signal (HI).
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able to detect linear autoubiquitination activity with wild type,
K48only and K63only ubiquitin linkages using TUBEs1 (Fig. 6b). The
signal for K48 only and K63 only ubiquitin were equivalent to one
another but 10 fold less than with wild type ubiquitin (Mdm2 has
several acceptor lysine residues and it has been shown to be able to
add multiple monoubiquitination)[17]. This line of experimentation
was followed with Traf6 as well. Traf6 autoubiquitinates using the E2
heterodimer Ubc13/Uev1a to form K63 linked polyubiquitin chains.
Uev1a contains the conserved enzymatic core of an E2 but lacks the
active site cysteine. It binds ubiquitin and positions the Lys63 toward
the catalytic cysteine of Ubc13 [18,19]. This selectively promotes the
K63 polyubiquitin chain formation on Traf6. We were unable to detect
activity with the K48 only or methylated ubiquitin derivatives as
expected. However, we did observe equivalent activity with K63 only
and wild type ubiquitin suggesting the primary linkage formation is
as reported with Traf6, primarily K63 linked chains (Fig. 6d). There is
also the potential for the formation of linear ubiquitin chains. The
signal proﬁle for linear chains would look similar to that of the
various linked chains, and therefore for either of these proteins we
cannot rule out that there is the conjugation of linear chains
occurring.
3.2. Suitability for drug discovery
We next examined the suitability of our assay for drug discovery
by carrying out a uniformity analysis to determine how the assay will
perform in a screening campaign. MDM2 reactions were carried out
in a 384 well plate as previously described, but for this experiment we
automated the liquid handling. Our results indicate that this assay
format would be well suited for drug discovery and high throughput
screening as we have a suitable signal to noise ratio of over 17 and our
z′ value for the plate was 0.72 (Fig. 7).
4. Discussion
We have developed and utilized many assay formats to identify
small molecule inhibitors of ubiquitin ligases to include each format
discussed. It is unknown as to whether tagged ubiquitin or proteins
inhibit the physiological mechanism of ubiquitin transfer, but the lack
of high quality chemical matter coming out of HTS campaigns in the
ubiquitin arena may suggest that they interfere, or that molecules
identiﬁed aren't acting on the native complex. The structures of di-
ubiquitin and tetra-ubiquitin [20] reveal no overt reasons as to why a
tag would interfere with the polyubiquitin chain integrity. Therefore
it is postulated that it might interfere with the kinetics of chain
elongation or conjugation. The undeﬁned mechanism of ubiquitin
transfer hampers discovery efforts. Here we developed a novel assay
that utilizes native ubiquitin that would help to eliminate thepotential for disruptions in the physiological mechanism. Recently, a
similar approach was described using ubiquitin binding domains as a
capture motif in a plate based format [21]. While this approach has its
advantages, one primary disadvantage is a wash step, which can add
complexity to a screening campaign. We set out to develop a novel
assay that incorporates the advantages of utilizing ubiquitin binding
domains but also incorporates the efﬁciency and simplicity of a
homogeneous format.
We were able to optimize the E1, E2 and E3 concentrations for an
Mdm2 autoubiquitination assay. Our results demonstrate that the
ubiquitin binding matrices do allow us to develop a means for
detection of polyubiquitination activity that is amenable for HTS. Our
ability to apply the assay technology to Hrd1, Traf6 and Smurf1 E3
ligases suggests that the assay may be universally adapted for other
E3 ligases. Furthermore, the TUBEs technology should also be well
suited for developing assays for multi subunit E3 ligases as their RING
containing proteins will similarly autoubiquitinate, or polyubiquiti-
nate substrates, in vitro.
Our MDM2 autoubiquitination assay had a signal to noise ratio of
over 17 and a z′ of 0.72, indicating that the TUBEs technology and the
assay format we have developed should be well suited for drug
discovery and HTS campaigns.
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